Cerveau Technologies Inc. Signs License and Supply Agreement with AbbVie for Novel Tau Imaging Agent

BOSTON–(BUSINESS WIRE)– Cerveau Technologies Inc. today announced a license and supply agreement with AbbVie for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.

Leave a Reply

Your email address will not be published. Required fields are marked *